We thank the core imaging facility of Institut Jacques Monod (ImagoSeine facility) for help in image acquisition and processing
superiority narrowly missed All-cause mortality: HR 0.86 (p=0.016, secondary analysis) LEADER Trial (Liraglutide)# The LEADER trial (Marso et al., NEJM 2016) enrolled 9,340 patients with T2D and high CV risk: Primary MACE: HR 0.87 (95% CI 0.78-0.97, p=0.01) CV death: HR 0.78 (22% reduction) All-cause mortality: HR 0.85 LEADER established liraglutide as the first GLP-1 agonist with proven cardiovascular superiority, a distinction exenatide did not achieve
As otolaryngologists, we really have to be on our game to sort out whats going on in these patients. As a guide for that detective work, I look for what I like to call break points in tinnitus, Dr
Sigari, N
My body needed the GLP-1 and clinical support, says Williams
More than just a weight loss calculator or calorie counter, the EZDietPlanner & Fitness Tracker allows you to easily follow the calorie specific meal plan and activity schedule Dr
